Skip to main content
Erschienen in: Infection 2/2019

29.11.2018 | Original Paper

Daptomycin vs. glycopeptides in the treatment of febrile neutropenia: results of the Izmir matched cohort study

verfasst von: Oguz Resat Sipahi, Hasip Kahraman, Huseyin Aytac Erdem, Funda Yetkin, Selcuk Kaya, Tuna Demirdal, Ozlem Guzel Tunccan, Omer Karasahin, Ebru Oruc, Yasemin Cag, Behice Kurtaran, Mehmet Ulug, Murat Kutlu, Meltem Avci, Nefise Oztoprak, Bilgin Arda, Husnu Pullukcu, Meltem Tasbakan, Tansu Yamazhan, Ozlem Kandemir, Murat Dizbay, Hilal Sipahi, Sercan Ulusoy

Erschienen in: Infection | Ausgabe 2/2019

Einloggen, um Zugang zu erhalten

Abstract

Purpose

In this multicentre, retrospective, matched cohort study we aimed to evaluate the outcomes of neutropenic fever cases that were treated with daptomycin or a glycopeptide (vancomycin or teicoplanin).

Methods

Data and outcomes of adult (aged > 18-years old) patients with neutropenic fever [(1) without clinical and radiological evidence of pneumonia, (2) who were treated with daptomycin or a glycopeptide (teicoplanin or vancomycin) for any reason and for at least 72 h] were extracted from the hospital databases. Matching was performed with all of the three following criteria: (1) underlying disease, (2) reason for starting daptomycin or glycopeptide (microbiologic evidence vs. microbiologic evidence, clinical infection vs. clinical infection and empirical therapy vs. empirical therapy) and (3) neutropenic status.

Results

Overall 128 patients [(69/123) (56.1%) in the daptomycin cohort (D) and 59/123 (48%) in the glycopeptide cohort (G)] had a resolution of fever at the end of 72 h antibiotic treatment (p = 0.25). There was no significant difference in cured, improved and (cured + improved) rates between (D) and (G) cohorts as well as fever of unknown origin cases or microbiologically confirmed infections or clinically defined infections subgroups (p > 0.05). There was also no significant difference (p > 0.05), in terms of persistent response in the (D) versus (G) cohorts,

Conclusions

These findings suggest that although not better, daptomycin efficacy is comparable to vancomycin if used as empiric therapy in the treatment of adult febrile neutropenia. We conclude that daptomycin may be used at least as a salvage therapy alternative to glycopeptides in the treatment of adult febrile neutropenia cases. A large, randomized-controlled trial may further consolidate the evidence related to this question.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Febrile Neutropenia Study Group. Guidelines for diagnosis and treatment of neutropenic patients. Flora. 2004;9:5–28. Febrile Neutropenia Study Group. Guidelines for diagnosis and treatment of neutropenic patients. Flora. 2004;9:5–28.
2.
Zurück zum Zitat Alp S, Akova M. Management of febrile neutropenia in the era of bacterial resistance. Ther Adv Infect Dis. 2013;1:37–43.PubMedPubMedCentral Alp S, Akova M. Management of febrile neutropenia in the era of bacterial resistance. Ther Adv Infect Dis. 2013;1:37–43.PubMedPubMedCentral
3.
Zurück zum Zitat Freifeld AG, Bow EJ, Sepkowitz KA, et al. Infectious Diseases Society of America. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 Update by the Infectious Diseases Society of America. Clin Infect Dis. 2011;52:427–31.CrossRefPubMed Freifeld AG, Bow EJ, Sepkowitz KA, et al. Infectious Diseases Society of America. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 Update by the Infectious Diseases Society of America. Clin Infect Dis. 2011;52:427–31.CrossRefPubMed
4.
Zurück zum Zitat Ozden M, Denk A, Demirdag K, et al. Investigation of febrile neutropenic cases and risk factors. Mediterr J Infect Microb Antimicrob. 2013;2:3. Ozden M, Denk A, Demirdag K, et al. Investigation of febrile neutropenic cases and risk factors. Mediterr J Infect Microb Antimicrob. 2013;2:3.
5.
Zurück zum Zitat Oztoprak N, Piskin N, Aydemir H, et al. Piperacillin-tazobactam versus carbapenem therapy with and without amikacin as empirical treatment of febrile neutropenia in cancer patients: results of an open randomized trial at a university hospital. Jpn J Clin Oncol. 2010;40:761–7.CrossRefPubMed Oztoprak N, Piskin N, Aydemir H, et al. Piperacillin-tazobactam versus carbapenem therapy with and without amikacin as empirical treatment of febrile neutropenia in cancer patients: results of an open randomized trial at a university hospital. Jpn J Clin Oncol. 2010;40:761–7.CrossRefPubMed
6.
Zurück zum Zitat Sipahi OR, Arda B, Nazli-Zeka A, et al. Piperacillin/tazobactam vs. cefoperazone/sulbactam in adult low-risk febrile neutropenia cases. Int J Clin Pract. 2014;68:230–5.CrossRefPubMed Sipahi OR, Arda B, Nazli-Zeka A, et al. Piperacillin/tazobactam vs. cefoperazone/sulbactam in adult low-risk febrile neutropenia cases. Int J Clin Pract. 2014;68:230–5.CrossRefPubMed
7.
Zurück zum Zitat Rolston KV, Besece D, Lamp KC, et al. Daptomycin use in neutropenic patients with documented gram-positive infections. Support Care Cancer. 2014;22:7–14.CrossRefPubMed Rolston KV, Besece D, Lamp KC, et al. Daptomycin use in neutropenic patients with documented gram-positive infections. Support Care Cancer. 2014;22:7–14.CrossRefPubMed
8.
Zurück zum Zitat Chaftari AM, Hachem R, Mulanovich V, et al. Efficacy and safety of daptomycin in the treatment of Gram-positive catheter-related bloodstream infections in cancer patients. Int J Antimicrob Agents. 2010;36:182–6.CrossRefPubMed Chaftari AM, Hachem R, Mulanovich V, et al. Efficacy and safety of daptomycin in the treatment of Gram-positive catheter-related bloodstream infections in cancer patients. Int J Antimicrob Agents. 2010;36:182–6.CrossRefPubMed
9.
Zurück zum Zitat Aktaş G, Derbentli S. In vitro activity of daptomycin against VRE and MRSA strains. Mikrobiyol Bul. 2014;48:123–8.PubMed Aktaş G, Derbentli S. In vitro activity of daptomycin against VRE and MRSA strains. Mikrobiyol Bul. 2014;48:123–8.PubMed
10.
Zurück zum Zitat Fowler VG Jr, Boucher HW, Corey GR, et al. Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus. N Engl J Med. 2006;355:653–65.CrossRefPubMed Fowler VG Jr, Boucher HW, Corey GR, et al. Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus. N Engl J Med. 2006;355:653–65.CrossRefPubMed
12.
Zurück zum Zitat Sipahi OR, Bardak-Ozcem S, Turhan T, et al. Vancomycin versus linezolid in the treatment of methicillin- resistant Staphylococcus aureus meningitis. Surg Infect (Larchmt). 2013;14:357–62.CrossRef Sipahi OR, Bardak-Ozcem S, Turhan T, et al. Vancomycin versus linezolid in the treatment of methicillin- resistant Staphylococcus aureus meningitis. Surg Infect (Larchmt). 2013;14:357–62.CrossRef
13.
Zurück zum Zitat Candevir-Ulu A, Kurtaran B, İnal AS, et al. Daptomycin experience between years 2009–2013: review of 139 cases. Mediterr J Infect Microb Antimicrob. 2014;3:23.CrossRef Candevir-Ulu A, Kurtaran B, İnal AS, et al. Daptomycin experience between years 2009–2013: review of 139 cases. Mediterr J Infect Microb Antimicrob. 2014;3:23.CrossRef
14.
Zurück zum Zitat Bubalo JS, Kullar R, Maziarz RT. A pilot study of the efficacy and safety of empiric daptomycin therapy in oncology patients with fever and severe neutropenia. Ther Adv Infect Dis. 2013;1:183–90.PubMedPubMedCentral Bubalo JS, Kullar R, Maziarz RT. A pilot study of the efficacy and safety of empiric daptomycin therapy in oncology patients with fever and severe neutropenia. Ther Adv Infect Dis. 2013;1:183–90.PubMedPubMedCentral
15.
Zurück zum Zitat Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing: twenty-third informational supplement M100-S23. Wayne: CLSI; 2013. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing: twenty-third informational supplement M100-S23. Wayne: CLSI; 2013.
16.
Zurück zum Zitat Molina KC, Huang V. Resistance to non-glycopeptide agents in serious Staphylococcus aureus infections. Curr Infect Dis Rep. 2016;18:47.CrossRefPubMed Molina KC, Huang V. Resistance to non-glycopeptide agents in serious Staphylococcus aureus infections. Curr Infect Dis Rep. 2016;18:47.CrossRefPubMed
17.
Zurück zum Zitat Vardakas KZ, Mavros MN, Roussos N, et al. Meta-analysis of randomized controlled trials of vancomycin for the treatment of patients with gram-positive infections: focus on the study design. Mayo Clin Proc. 2012;87:349–63.CrossRefPubMedPubMedCentral Vardakas KZ, Mavros MN, Roussos N, et al. Meta-analysis of randomized controlled trials of vancomycin for the treatment of patients with gram-positive infections: focus on the study design. Mayo Clin Proc. 2012;87:349–63.CrossRefPubMedPubMedCentral
18.
Zurück zum Zitat Moise PA, Sakoulas G, Forrest A, et al. Vancomycin in vitro bactericidal activity and its relationship to efficacy in clearance of methicillin-resistant Staphylococcus aureus bacteremia. Antimicrob Agents Chemother. 2007;51:2582–6.CrossRefPubMedPubMedCentral Moise PA, Sakoulas G, Forrest A, et al. Vancomycin in vitro bactericidal activity and its relationship to efficacy in clearance of methicillin-resistant Staphylococcus aureus bacteremia. Antimicrob Agents Chemother. 2007;51:2582–6.CrossRefPubMedPubMedCentral
19.
Zurück zum Zitat Gould IM. Treatment of bacteraemia: meticillin-resistant Staphylococcus aureus (MRSA) to vancomycin-resistant S. aureus (VRSA). Int J Antimicrob Agents. 2013;42:17–21.CrossRef Gould IM. Treatment of bacteraemia: meticillin-resistant Staphylococcus aureus (MRSA) to vancomycin-resistant S. aureus (VRSA). Int J Antimicrob Agents. 2013;42:17–21.CrossRef
20.
Zurück zum Zitat Jaksic B, Martinelli G, Perez-Oteyza J, et al. Efficacy and safety of linezolid compared with vancomycin in a randomized, double-blind study of febrile neutropenic patients with cancer. Clin Infect Dis. 2006;42:597–607.CrossRefPubMed Jaksic B, Martinelli G, Perez-Oteyza J, et al. Efficacy and safety of linezolid compared with vancomycin in a randomized, double-blind study of febrile neutropenic patients with cancer. Clin Infect Dis. 2006;42:597–607.CrossRefPubMed
21.
Zurück zum Zitat Murray KP, Zhao JJ, Davis SL, et al. Early use of daptomycin versus vancomycin for methicillin-resistant Staphylococcus aureus bacteremia with vancomycin minimum inhibitory concentration> 1 mg/L: a matched cohort study. Clin Infect Dis. 2013;56:1562–9.CrossRefPubMed Murray KP, Zhao JJ, Davis SL, et al. Early use of daptomycin versus vancomycin for methicillin-resistant Staphylococcus aureus bacteremia with vancomycin minimum inhibitory concentration> 1 mg/L: a matched cohort study. Clin Infect Dis. 2013;56:1562–9.CrossRefPubMed
22.
Zurück zum Zitat Heinz WJ, Buchheidt D, Christopeit M, et al. Diagnosis and empirical treatment of fever of unknown origin (FUO) in adult neutropenic patients: guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Medical Oncology (DGHO). Ann Hematol. 2017;96:1775–92.CrossRefPubMedPubMedCentral Heinz WJ, Buchheidt D, Christopeit M, et al. Diagnosis and empirical treatment of fever of unknown origin (FUO) in adult neutropenic patients: guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Medical Oncology (DGHO). Ann Hematol. 2017;96:1775–92.CrossRefPubMedPubMedCentral
23.
Zurück zum Zitat Chong PP, van Duin D, Bangdiwala A, et al. Vancomycin-resistant enterococcal bloodstream infections in hematopoietic stem cell transplant recipients and patients with hematologic malignancies: impact of daptomycin MICs of 3 to 4 mg/L. Clin Ther. 2016;38:2468–76.CrossRefPubMed Chong PP, van Duin D, Bangdiwala A, et al. Vancomycin-resistant enterococcal bloodstream infections in hematopoietic stem cell transplant recipients and patients with hematologic malignancies: impact of daptomycin MICs of 3 to 4 mg/L. Clin Ther. 2016;38:2468–76.CrossRefPubMed
25.
27.
Zurück zum Zitat Bülüç F, Ozkan O, Agirbas İ. Evaluation of financial performance of university hospitals by ratio analysis method. Bus Manag Stud Int J. 2017;5:268-281. Bülüç F, Ozkan O, Agirbas İ. Evaluation of financial performance of university hospitals by ratio analysis method. Bus Manag Stud Int J. 2017;5:268-281.
Metadaten
Titel
Daptomycin vs. glycopeptides in the treatment of febrile neutropenia: results of the Izmir matched cohort study
verfasst von
Oguz Resat Sipahi
Hasip Kahraman
Huseyin Aytac Erdem
Funda Yetkin
Selcuk Kaya
Tuna Demirdal
Ozlem Guzel Tunccan
Omer Karasahin
Ebru Oruc
Yasemin Cag
Behice Kurtaran
Mehmet Ulug
Murat Kutlu
Meltem Avci
Nefise Oztoprak
Bilgin Arda
Husnu Pullukcu
Meltem Tasbakan
Tansu Yamazhan
Ozlem Kandemir
Murat Dizbay
Hilal Sipahi
Sercan Ulusoy
Publikationsdatum
29.11.2018
Verlag
Springer Berlin Heidelberg
Erschienen in
Infection / Ausgabe 2/2019
Print ISSN: 0300-8126
Elektronische ISSN: 1439-0973
DOI
https://doi.org/10.1007/s15010-018-1256-8

Weitere Artikel der Ausgabe 2/2019

Infection 2/2019 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.